XML 99 R2.htm IDEA: XBRL DOCUMENT
v3.25.1

Pay vs Performance Disclosure - USD ($) | 12 Months Ended
--- | ---
Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Pay vs Performance Disclosure |  |  |  |  |
Pay vs Performance Disclosure, Table | Pay Versus Pe rformance As required, below is disclosure of the compensation of the Company’s Named Executive Officers, or NEOs, for the last five fiscal years calculated in accordance with Item 402(v) of Regulation S-K. Item 402(v) requires disclosure of “compensation actually paid” based on calculations that report changes in the fair value of equity awards granted in prior years, granted during the fiscal year, and vesting during the fiscal year, but that do not reflect the actual amount of compensation earned or received by any of the NEOs during the fiscal year. For information about our compensation philosophy and how we align executive compensation with our performance, please see our "Compensation Discussion and Analysis."
|  |  |  |  |  |  |  |  |  |  |  |  |  | Value of Initial Fixed $100 Investment Based on: |  |  |  |  |  |  |
Year |  | Summary Compensation Table Total for CEO($) |  |  | Compensation Actually Paid to CEO($)(1)(2) |  |  | Average Summary Compensation Table Total for Non-CEO Named Executive Officers($) |  |  | Average Compensation Actually Paid to Non-CEO Named Executive Officers(1)(2) |  |  | Amgen Total Shareholder Return($)(3) |  |  | Peer Group Total Shareholder Return ($)(3)(4) |  |  | Net Income ($M) |  |  | Non-GAAP EPS($)(5) |
2024 |  |  | 24,428,495 |  |  |  | 12,659,979 |  |  |  | 9,830,379 |  |  |  | 6,673,884 |  |  |  | 125.95 |  |  |  | 152.85 |  |  |  | 4,090 |  |  |  | 19.36 |
2023 |  |  | 22,643,650 |  |  |  | 29,105,407 |  |  |  | 7,730,150 |  |  |  | 9,701,292 |  |  |  | 135.10 |  |  |  | 140.88 |  |  |  | 6,717 |  |  |  | 18.83 |
2022 |  |  | 21,399,733 |  |  |  | 41,655,553 |  |  |  | 7,211,427 |  |  |  | 12,777,767 |  |  |  | 119.07 |  |  |  | 140.24 |  |  |  | 6,552 |  |  |  | 17.18 |
2021 |  |  | 21,721,154 |  |  |  | 17,040,728 |  |  |  | 7,358,134 |  |  |  | 5,869,521 |  |  |  | 98.87 |  |  |  | 126.57 |  |  |  | 5,893 |  |  |  | 17.69 |
2020 |  |  | 20,131,408 |  |  |  | 14,724,312 |  |  |  | 6,736,942 |  |  |  | 5,571,375 |  |  |  | 98.01 |  |  |  | 102.65 |  |  |  | 7,264 |  |  |  | 16.60 |
(1) As the valuation methods for “compensation actually paid” required by the SEC differ from those required in the Summary Compensation Table (“SCT”), the table below provides a reconciliation of SCT amounts to the Compensation Actually Paid (“CAP”) amounts in the Pay Versus Performance table for Mr. Bradway and the average SCT and CAP amounts for our other NEOs for each of the last five fiscal years. The other non-CEO NEOs for each of 2023, 2022, 2021, and 2020 include Messrs. Gordon and Griffith, Dr. Reese, and Esteban Santos, Executive Vice President, Operations. The other non-CEO NEOs for 2024 include Messrs. Gordon and Griffith and Drs. Bradner and Reese. Summary Compensation Table to Compensation Actually Paid Reconciliation Table
|  |  |  | Required Adjustments to Summary Compensation Table Totals to Determine "Compensation Actually Paid" |  |
|  | Year |  | Summary Compensation Table Total($) |  | Summary Compensation Table Value of Stock Awards($) |  | Summary Compensation Table Value of Option Awards($) |  | Fair Value as of Year End of Equity Awards Granted During the Year($) |  | Year-Over- Year Increase (Decrease) in Fair Value as of Year End of Unvested Awards Granted in Prior Years($) |  | Increase (Decrease) From Prior Year End in Fair Value of Awards That Vested During the Year($) | Compensation Actually Paid($) |
|  |  |  | (a) |  | (b) |  | (c) |  | (d) |  | (e) |  | (f) | (g)=(a)-(b)-(c)+(d)+(e)+(f) |
Robert A. Bradway |  | 2024 |  | 24,428,495 |  | 12,599,930 |  | 5,399,991 |  | 13,982,336 |  | (6,132,458) |  | (1,618,473) | 12,659,979 |
Average of Other |  | 2024 |  | 9,830,379 |  | 4,989,376 |  | 1,439,967 |  | 4,981,274 |  | (1,346,561) |  | (361,865) | 6,673,884 |
NEOs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
(2) Stock option fair values are calculated at each measurement date using a Black-Scholes valuation model, consistent with the approach used to value the awards at the grant date. Stock option fair values as of each measurement date were determined using updated assumptions as of such measurement date that include closing prices of our Common Stock of between $260.64 and $311.29, risk-free interest rates of between 4.2% and 4.9%, expected life of between 1.3 and 5.9 years, expected volatility of the price of our Common Stock of between 24.6% and 26.5%, and expected dividend yields of 3.2%. Changes in fair value are primarily driven by increases or decreases in the price of the Company’s Common Stock as of each measurement date. Performance unit fair values are calculated using a payout simulation model, consistent with the approach used to value the awards at the grant date. Performance unit fair values as of each measurement date were determined using updated assumptions as of such measurement date that include risk-free interest rates of between 4.1% and 4.2%, expected volatility of the price of our Common Stock of between 23.3% and 25.5%, the closing price of our Common Stock of $260.64, and expected volatilities of the prices of the stocks of the Reference Group (as defined in footnote 3 to the “Grant of Plan-Based Awards” table in our Executive Compensation Tables), and the correlations of returns of our Common Stock and the stocks of the Reference Group to simulate total shareholder returns and their resulting impact on the payout percentages based on the contractual terms of the performance units). Changes in fair value are primarily driven by increases or decreases in the price of the Company’s Common Stock as of each measurement date. (3) Pursuant to the SEC rules, total shareholder return, or TSR, reflects an initial investment of $100 on December 31, 2019. All values assume reinvestment of the pretax value of dividends, are calculated as of December 31 of each year, and are weighted according to the respective issuers’ stock market capitalization at the beginning of each period for which a return is indicated. (4) The peer group for each listed fiscal year consists of the companies listed as our executive compensation benchmarking peer group in the Compensation Discussion and Analysis for 2024, including AbbVie, Inc.; AstraZeneca plc; Biogen Inc.; Bristol Myers Squibb Company; Eli Lilly and Company; Gilead Sciences, Inc.; GlaxoSmithKline plc.; Johnson & Johnson; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Roche Holding AG; and Sanofi S.A. Allergan plc and Celgene Corporation were removed from our executive compensation benchmarking peer group in July 2020 following their acquisitions by AbbVie Inc. and Bristol-Myers Squibb Company, respectively. (5) Non-Generally Accepted Accounting Principles, or non-GAAP, earnings per share, or EPS, for purposes of the Company selected measure is reported and reconciled (A) for 2024, 2023, and 2022 in Appendix B, except that non-GAAP EPS was further adjusted for: (i) 2024 as described on page 59 of our Compensation Discussion and Analysis; (ii) 2023 as described on page 59 of our 2024 proxy statement filed with the SEC on April, 17, 2024, or the 2024 Proxy Statement; and (iii) 2022 as described on page 52 of our 2023 proxy statement filed with the SEC on April 6, 2023, or the 2023 Proxy Statement, and (B) for 2021 and 2020, in Appendix B to the 2023 Proxy Statement, except that non-GAAP EPS for 2021 was further adjusted as described on page 50 of our 2022 proxy statement filed with the SEC on April, 5, 2022, or the 2022 Proxy Statement. |  |  |  |
Company Selected Measure Name | non-GAAP, earnings per share, or EPS |  |  |  |
Named Executive Officers, Footnote | The other non-CEO NEOs for 2024 include Messrs. Gordon and Griffith and Drs. Bradner and Reese. |  |  |  |
Peer Group Issuers, Footnote | (4) The peer group for each listed fiscal year consists of the companies listed as our executive compensation benchmarking peer group in the Compensation Discussion and Analysis for 2024, including AbbVie, Inc.; AstraZeneca plc; Biogen Inc.; Bristol Myers Squibb Company; Eli Lilly and Company; Gilead Sciences, Inc.; GlaxoSmithKline plc.; Johnson & Johnson; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Roche Holding AG; and Sanofi S.A. Allergan plc and Celgene Corporation were removed from our executive compensation benchmarking peer group in July 2020 following their acquisitions by AbbVie Inc. and Bristol-Myers Squibb Company, respectively. |  |  |  |
PEO Total Compensation Amount | $ 24,428,495 | $ 22,643,650 | $ 21,399,733 | $ 21,721,154 | $ 20,131,408
PEO Actually Paid Compensation Amount | $ 12,659,979 | 29,105,407 | 41,655,553 | 17,040,728 | 14,724,312
Adjustment To PEO Compensation, Footnote | Summary Compensation Table to Compensation Actually Paid Reconciliation Table
|  |  |  | Required Adjustments to Summary Compensation Table Totals to Determine "Compensation Actually Paid" |  |
|  | Year |  | Summary Compensation Table Total($) |  | Summary Compensation Table Value of Stock Awards($) |  | Summary Compensation Table Value of Option Awards($) |  | Fair Value as of Year End of Equity Awards Granted During the Year($) |  | Year-Over- Year Increase (Decrease) in Fair Value as of Year End of Unvested Awards Granted in Prior Years($) |  | Increase (Decrease) From Prior Year End in Fair Value of Awards That Vested During the Year($) | Compensation Actually Paid($) |
|  |  |  | (a) |  | (b) |  | (c) |  | (d) |  | (e) |  | (f) | (g)=(a)-(b)-(c)+(d)+(e)+(f) |
Robert A. Bradway |  | 2024 |  | 24,428,495 |  | 12,599,930 |  | 5,399,991 |  | 13,982,336 |  | (6,132,458) |  | (1,618,473) | 12,659,979 |
Average of Other |  | 2024 |  | 9,830,379 |  | 4,989,376 |  | 1,439,967 |  | 4,981,274 |  | (1,346,561) |  | (361,865) | 6,673,884 |
NEOs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-PEO NEO Average Total Compensation Amount | $ 9,830,379 | 7,730,150 | 7,211,427 | 7,358,134 | 6,736,942
Non-PEO NEO Average Compensation Actually Paid Amount | $ 6,673,884 | 9,701,292 | 12,777,767 | 5,869,521 | 5,571,375
Adjustment to Non-PEO NEO Compensation Footnote | Summary Compensation Table to Compensation Actually Paid Reconciliation Table
|  |  |  | Required Adjustments to Summary Compensation Table Totals to Determine "Compensation Actually Paid" |  |
|  | Year |  | Summary Compensation Table Total($) |  | Summary Compensation Table Value of Stock Awards($) |  | Summary Compensation Table Value of Option Awards($) |  | Fair Value as of Year End of Equity Awards Granted During the Year($) |  | Year-Over- Year Increase (Decrease) in Fair Value as of Year End of Unvested Awards Granted in Prior Years($) |  | Increase (Decrease) From Prior Year End in Fair Value of Awards That Vested During the Year($) | Compensation Actually Paid($) |
|  |  |  | (a) |  | (b) |  | (c) |  | (d) |  | (e) |  | (f) | (g)=(a)-(b)-(c)+(d)+(e)+(f) |
Robert A. Bradway |  | 2024 |  | 24,428,495 |  | 12,599,930 |  | 5,399,991 |  | 13,982,336 |  | (6,132,458) |  | (1,618,473) | 12,659,979 |
Average of Other |  | 2024 |  | 9,830,379 |  | 4,989,376 |  | 1,439,967 |  | 4,981,274 |  | (1,346,561) |  | (361,865) | 6,673,884 |
NEOs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity Valuation Assumption Difference, Footnote | (2) Stock option fair values are calculated at each measurement date using a Black-Scholes valuation model, consistent with the approach used to value the awards at the grant date. Stock option fair values as of each measurement date were determined using updated assumptions as of such measurement date that include closing prices of our Common Stock of between $260.64 and $311.29, risk-free interest rates of between 4.2% and 4.9%, expected life of between 1.3 and 5.9 years, expected volatility of the price of our Common Stock of between 24.6% and 26.5%, and expected dividend yields of 3.2%. Changes in fair value are primarily driven by increases or decreases in the price of the Company’s Common Stock as of each measurement date. Performance unit fair values are calculated using a payout simulation model, consistent with the approach used to value the awards at the grant date. Performance unit fair values as of each measurement date were determined using updated assumptions as of such measurement date that include risk-free interest rates of between 4.1% and 4.2%, expected volatility of the price of our Common Stock of between 23.3% and 25.5%, the closing price of our Common Stock of $260.64, and expected volatilities of the prices of the stocks of the Reference Group (as defined in footnote 3 to the “Grant of Plan-Based Awards” table in our Executive Compensation Tables), and the correlations of returns of our Common Stock and the stocks of the Reference Group to simulate total shareholder returns and their resulting impact on the payout percentages based on the contractual terms of the performance units). Changes in fair value are primarily driven by increases or decreases in the price of the Company’s Common Stock as of each measurement date. |  |  |  |
Compensation Actually Paid vs. Total Shareholder Return | (1) Compensation Actually Paid Compared to Total Shareholder Return
Compensation Actually Paid vs. Net Income | (2) Compensation Actually Paid Compared to Net Income
Compensation Actually Paid vs. Company Selected Measure | (3) Compensation Actually Paid Compared to Non-GAAP EPS
Total Shareholder Return Vs Peer Group | (1) Compensation Actually Paid Compared to Total Shareholder Return
Tabular List, Table | 2024 Performance Measures Pursuant to Item 402(v) of Regulation S-K, the Compensation Committee identified the following financial and non-financial performance measures used in our long-term and annual incentive programs as representing the most important performance measures used to link “compensation actually paid” in 2024 to the Company’s performance.
• Non-GAAP earnings per share (EPS) • Non-GAAP return on invested capital (ROIC) • Total shareholder return (TSR) relative to that of the S&P 500 • Revenues | • Non-GAAP net income • Pipeline, clinical study, and regulatory goals • Sustainability and integration goals
For a description of these measures and their application to our compensation programs for 2024, please see our Compensation Discussion and Analysis. |  |  |  |
Total Shareholder Return Amount | $ 125.95 | 135.1 | 119.07 | 98.87 | 98.01
Peer Group Total Shareholder Return Amount | 152.85 | 140.88 | 140.24 | 126.57 | 102.65
Net Income (Loss) | $ 4,090,000,000 | $ 6,717,000,000 | $ 6,552,000,000 | $ 5,893,000,000 | $ 7,264,000,000
Company Selected Measure Amount | 19.36 | 18.83 | 17.18 | 17.69 | 16.6
PEO Name | Mr. Bradway |  |  |  |
Measure:: 1 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Non-GAAP earnings per share (EPS) |  |  |  |
Non-GAAP Measure Description | (5) Non-Generally Accepted Accounting Principles, or non-GAAP, earnings per share, or EPS, for purposes of the Company selected measure is reported and reconciled (A) for 2024, 2023, and 2022 in Appendix B, except that non-GAAP EPS was further adjusted for: (i) 2024 as described on page 59 of our Compensation Discussion and Analysis; (ii) 2023 as described on page 59 of our 2024 proxy statement filed with the SEC on April, 17, 2024, or the 2024 Proxy Statement; and (iii) 2022 as described on page 52 of our 2023 proxy statement filed with the SEC on April 6, 2023, or the 2023 Proxy Statement, and (B) for 2021 and 2020, in Appendix B to the 2023 Proxy Statement, except that non-GAAP EPS for 2021 was further adjusted as described on page 50 of our 2022 proxy statement filed with the SEC on April, 5, 2022, or the 2022 Proxy Statement. |  |  |  |
Measure:: 2 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Non-GAAP return on invested capital (ROIC) |  |  |  |
Measure:: 3 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Total shareholder return (TSR) relative to that of the S&P 500 |  |  |  |
Measure:: 4 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Revenues |  |  |  |
Measure:: 5 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Non-GAAP net income |  |  |  |
Measure:: 6 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Pipeline, clinical study, and regulatory goals |  |  |  |
Measure:: 7 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Sustainability and integration goals |  |  |  |
Stock Option Fair Values |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Common Stock Closing Price, Minimum | $ 260.64 |  |  |  |
Common Stock Closing Price, Maximum | $ 311.29 |  |  |  |
Risk Free Interest Rate, Minimum | 4.20% |  |  |  |
Risk Free Interest Rate, Maximum | 4.90% |  |  |  |
Expected Life, Minimum | 1 year 3 months 18 days |  |  |  |
Expected Life, Maximum | 5 years 10 months 24 days |  |  |  |
Expected Volatility Rate, Minimum | 24.60% |  |  |  |
Expected Volatility Rate, Maximum | 26.50% |  |  |  |
Expected Dividend Yield | 3.20% |  |  |  |
Performance Unit Fair Values |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Risk Free Interest Rate, Minimum | 4.10% |  |  |  |
Risk Free Interest Rate, Maximum | 4.20% |  |  |  |
Expected Volatility Rate, Minimum | 23.30% |  |  |  |
Expected Volatility Rate, Maximum | 25.50% |  |  |  |
Common Stock Closing Price | $ 260.64 |  |  |  |
PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | $ 13,982,336 |  |  |  |
PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (6,132,458) |  |  |  |
PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (1,618,473) |  |  |  |
PEO | Summary Compensation Table Value of Stock Awards [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (12,599,930) |  |  |  |
PEO | Summary Compensation Table Value of Option Awards [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (5,399,991) |  |  |  |
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 4,981,274 |  |  |  |
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (1,346,561) |  |  |  |
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (361,865) |  |  |  |
Non-PEO NEO | Summary Compensation Table Value of Stock Awards [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (4,989,376) |  |  |  |
Non-PEO NEO | Summary Compensation Table Value of Option Awards [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | $ (1,439,967) |  |  |  |

X
- Definition Common stock closing price. + References No definition available. + Details
Name: | amgn_CommonStockClosingPrice
Namespace Prefix: | amgn_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Common stock closing price, maximum. + References No definition available. + Details
Name: | amgn_CommonStockClosingPriceMaximum
Namespace Prefix: | amgn_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Common stock closing price, minimum. + References No definition available. + Details
Name: | amgn_CommonStockClosingPriceMinimum
Namespace Prefix: | amgn_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Expected dividend yield. + References No definition available. + Details
Name: | amgn_ExpectedDividendYield
Namespace Prefix: | amgn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Expected life, maximum. + References No definition available. + Details
Name: | amgn_ExpectedLifeMaximum
Namespace Prefix: | amgn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Expected Life, Minimum + References No definition available. + Details
Name: | amgn_ExpectedLifeMinimum
Namespace Prefix: | amgn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Expected volatility rate, maximum. + References No definition available. + Details
Name: | amgn_ExpectedVolatilityRateMaximum
Namespace Prefix: | amgn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Expected volatility rate, minimum. + References No definition available. + Details
Name: | amgn_ExpectedVolatilityRateMinimum
Namespace Prefix: | amgn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Risk free interest rate, maximum. + References No definition available. + Details
Name: | amgn_RiskFreeInterestRateMaximum
Namespace Prefix: | amgn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Risk Free Interest Rate Minimum + References No definition available. + Details
Name: | amgn_RiskFreeInterestRateMinimum
Namespace Prefix: | amgn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToNonPeoNeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToPeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iii + Details
Name: | ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph ii + Details
Name: | ecd_CompActuallyPaidVsNetIncomeTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph i + Details
Name: | ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 4 + Details
Name: | ecd_EquityValuationAssumptionDifferenceFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_MeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_NamedExecutiveOfficersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_NonGaapMeasureDescriptionTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_NonPeoNeoAvgCompActuallyPaidAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_NonPeoNeoAvgTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupIssuersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupTotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_PeoActuallyPaidCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_PeoName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_PeoTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 6 + Details
Name: | ecd_TabularListTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnVsPeerGroupTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7 Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ecd_MeasureAxis=1
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=2
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=3
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=4
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=5
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=6
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=7
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=amgn_StockOptionFairValuesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=amgn_PerformanceUnitFairValuesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_PeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=amgn_SummaryCompensationTableValueOfStockAwardsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=amgn_SummaryCompensationTableValueOfOptionAwardsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |